Institute of Anatomy and Experimental Morphology, University Medical Center Hamburg-Eppendorf, Germany.
Cancer Lett. 2011 Sep 1;308(1):54-61. doi: 10.1016/j.canlet.2011.04.013. Epub 2011 May 12.
HER-2/neu over-expression occurs in 10-40% of patients with esophageal adenocarcinoma. Therefore, inhibitory effects of trastuzumab on proliferation, neoangiogenesis and metastatic spread of the esophageal adenocarcinoma cell line PT1590 were investigated (subcutaneous xenograft model). PT1590 revealed an amplified copy number of c-erbB2 and HER-2/neu over-expression occured in xenograft tumors and spontaneous lung metastases. PT1590 proliferation was significantly inhibited by trastuzumab in vitro. In vivo, tumor weight, volume, microvessel density and number of lung metastases decreased significantly after three weeks of treatment. These data suggest the importance of HER-2/neu for metastatic spread in esophageal adenocarcinoma and encourages clinical trials.
人表皮生长因子受体-2（HER-2/neu）过表达发生于 10%-40%的食管腺癌患者中。因此，我们研究了曲妥珠单抗对食管腺癌细胞系 PT1590 的增殖、新生血管形成和转移扩散的抑制作用（皮下移植瘤模型）。PT1590 存在 c-erbB2 拷贝数扩增，且在移植瘤和自发性肺转移中存在 HER-2/neu 过表达。曲妥珠单抗在体外显著抑制了 PT1590 的增殖。在体内，治疗 3 周后，肿瘤重量、体积、微血管密度和肺转移数目均显著降低。这些数据提示 HER-2/neu 对食管腺癌转移扩散的重要性，并鼓励开展临床试验。
